Cargando…
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
OBJECTIVES: The SARS-CoV-2 Omicron variant presents numerous mutations potentially able to evade neutralizing antibodies (NAbs) elicited by COVID-19 vaccines. Therefore, this study aimed to provide evidence on a heterologous booster strategy to overcome the waning immunity against Omicron variants....
Autores principales: | Assawakosri, Suvichada, Kanokudom, Sitthichai, Chansaenroj, Jira, Suntronwong, Nungruthai, Auphimai, Chompoonut, Nilyanimit, Pornjarim, Vichaiwattana, Preeyaporn, Thongmee, Thanunrat, Duangchinda, Thaneeya, Chantima, Warangkana, Pakchotanon, Pattarakul, Srimuan, Donchida, Thatsanatorn, Thaksaporn, Klinfueng, Sirapa, Sudhinaraset, Natthinee, Mongkolsapaya, Juthathip, Wanlapakorn, Nasamon, Honsawek, Sittisak, Poovorawan, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293855/ https://www.ncbi.nlm.nih.gov/pubmed/35863731 http://dx.doi.org/10.1016/j.ijid.2022.07.038 |
Ejemplares similares
-
Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
por: Suntronwong, Nungruthai, et al.
Publicado: (2022) -
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022) -
COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
por: Suntronwong, Nungruthai, et al.
Publicado: (2022) -
The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
por: Kanokudom, Sitthichai, et al.
Publicado: (2023) -
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
por: Chansaenroj, Jira, et al.
Publicado: (2022)